| Similar Articles |
|---|
 |
Bio-IT World
March 17, 2004 |
Signs of Spring Colin Hill, CEO of Gene Network Sciences, a predictive systems biology company, says the worst is behind the bio-IT industry. "The hype has dissipated, and companies are focused on delivering the results," he says. Hill's strategy includes developing additional products, which should generate near-term revenue.   |
Bio-IT World
May 9, 2003
Michael Greeley |
Mechanistic Models Investors are backing predictive modeling software that could speed drug development. |
Bio-IT World
February 2006
John Russell |
Marvelous Models of Biological Systems Here are highlights from a roundtable discussion with researchers representing academia and pharmaceuticals, as well as executives from modeling technology providers on whether or not Pharma is ready to bet on computational modeling of biological systems. |
Bio-IT World
October 2006
John Russell |
GNS Charts "Unknown" Biology Gene Network Sciences' CEO and colleagues now think they have the right tool to mine the treasure trove of unknown biology hidden in the wealth of accumulating omic data. |
Bio-IT World
June 2006
Michael A. Greeley |
Backwards Influence Biotech companies must think downstream as they consider what drugs to develop. Many companies are introducing cost-effectiveness analysis earlier in the discovery process. |
Bio-IT World
January 13, 2003
Michael Greeley |
What Do We Do Now? Like it or not, the supply of capital is an important ingredient in the continued development of the bio-IT industry. Appreciating and understanding the forces currently at work in the VC marketplace can only help in raising capital. |
Bio-IT World
September 2005
Michael A. Greeley |
Harvesting Patient Data Longitudinal data tools will allow pharmaceuticals to optimize sales force deployments and distribution strategies based on medical impacts of their compounds across various population sets. |
Pharmaceutical Executive
February 1, 2006
Ron Feemster |
Gene Logic: Rescue Squad One or two late-stage clinical failures can land promising drug candidates on the shelf. Forever? Maybe not. Gene Logic tests Big Pharma's dead drugs for hundreds of different targets. |
Bio-IT World
July 11, 2002
Kevin Davies |
Counting the Cost of Drug Discovery Much of the trouble ensnaring the drug industry is blamed on the exorbitant cost of drug discovery. Tangible proof that the bio-IT revolution will economize drug discovery is emerging, but there is still a long way to go. |
Bio-IT World
October 2005
Michael A. Greeley |
Biomarkers Redux How the biomarker discovery industry evolves is still under debate. It is clear that many approaches will need to coexist to give a complete understanding of a particular sample; this troubles many VCs, as small and emerging markets are not good at supporting numerous competing solutions. |
Bio-IT World
April 2006
Michael A. Greeley |
The Good, The Bad, and The Ugly VCs will not support a sector where consistent compelling exits are not evident. Unfortunately, the bio-IT field still suffers from this. |
Bio-IT World
Dec 2005/Jan 2006
Michael A. Greeley |
Infinite Demand for the Unavailable The bio-IT field is once again attracting venture capital, but at a more moderate, deliberate pace than the euphoria of the late 1990s. |
The Motley Fool
August 8, 2007
Brian Lawler |
Array's Bright Pipeline Array BioPharma announces its goals for the months ahead in its fourth-quarter results. What is interesting is the varied mix of new compounds in their pipeline. |
Bio-IT World
October 10, 2003 |
Funds Up Venture financing numbers are in for Q2, and the news is not all bad. |
Bio-IT World
July 15, 2003
Michael Greeley |
Finally, the Bottom Has pharma bought all the solutions it needs? The flood of genomic data indicates no. |
Bio-IT World
October 14, 2004
Michael Greeley |
Go East Business is great in China, and the government is strongly encouraging the local biotech industry. |
Bio-IT World
June 12, 2002
Morris R. Levitt |
A New Economic Paradigm for Bio-IT? All who work in the bio-IT industry -- scientists, IT and informatics managers, and executives -- have been aware for some time that we seem to be suspended between an acute sense of crisis and a field of boundless opportunity. |
Bio-IT World
April 15, 2003
Michael Greeley |
Bio Battles Upstream As biotech business models evolve, the question remains: Which will survive? |
Chemistry World
September 2007
Derek Lowe |
Column: In the Pipeline Will Phase Zero trials actually help drug development? |
Inc.
July 2006
Darren Dahl |
CEOs Are From Mars, VCs Are From Venus It's official: CEOs ans VCs see everything differently. |
InternetNews
April 30, 2010 |
Software Sector Poised for Rebound New reporting from venture capital firm Sand Hill Group finds IT executives are getting bullish again, with plans to ramp up spending on long-deferred projects and resume hiring. |
Bio-IT World
September 11, 2003 |
Show Me the Evidence ... Some emerging bio-IT services companies are beginning to attract venture capital. |
Bio-IT World
January 12, 2004
Michael A. Greeley |
What You See Is What You Get Better image analysis, better business models. The transition from analog to digital will allow systems biology to reach its full potential. |
CIO
September 15, 2002
Gary Beach |
A New Pitch Startup tech CEOs may know technology, but they are clueless about marketing. |
Bio-IT World
October 9, 2002
Debra Goldfarb |
A Study in Contrasts Recently, IDC conducted a pair of focus groups as part of a broader study on technology adoption across bio-IT workloads. |
Bio-IT World
March 10, 2003
Michael Greeley |
Too Much Informatics Did bioinformatics companies forget about the fundamental law of supply and demand? |
Bio-IT World
March 8, 2005
Michael A. Greeley |
What's New at Big Blue? The scale of computing has improved dramatically in the life sciences. But has the bio-IT industry over-promised, and does it risk under-delivering? Ultimately, customers will want to see a return on these investments, and that won't happen in two to three years. |
